Oncology drug developers must start asking questions in preparation of FDA’s dose optimization initiative.
Julie Bullock
Advertisement
SVP, Clinical Pharmacology & Translational Medicine
Articles by Julie Bullock
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on PharmExec
1
Roundup: FDA Approves Novo Nordisk's Rybelsus and Roche’s Gazyva/Gazyvaro
2
Merck Planning $70 Billion Investment for US Expansion
3
FDA Approves Tezspire as First Biologic Targeting TSLP for Chronic Rhinosinusitis With Nasal Polyps
4
Amazon and WeightWatchers Partner for DTC Weight Loss Medication Offerings
5
